Published in Brain Pathol on February 20, 2009
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain (2011) 1.48
Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. Protein Cell (2010) 1.45
Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem (2009) 1.35
Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med (2013) 1.14
Structures, biosynthesis, and functions of gangliosides--an overview. J Oleo Sci (2011) 1.11
Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res (2012) 1.11
Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci (2011) 1.08
Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB. Cell Death Differ (2014) 1.03
What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol (2013) 1.02
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett (2010) 0.98
Twisted tango: brain tumor neurovascular interactions. Nat Neurosci (2011) 0.95
Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov (2014) 0.95
Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep (2013) 0.93
Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis (2014) 0.93
Membrane glycolipids in stem cells. FEBS Lett (2009) 0.93
Cancer stem cell subsets and their relationships. J Transl Med (2011) 0.89
Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer (2010) 0.89
NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene (2013) 0.87
Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget (2014) 0.86
CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. PLoS One (2015) 0.86
Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev (2013) 0.84
Increased Oxidative Stress as a Selective Anticancer Therapy. Oxid Med Cell Longev (2015) 0.83
Chemotherapy targeting cancer stem cells. Am J Cancer Res (2015) 0.83
End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. Oncotarget (2014) 0.81
Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc Natl Acad Sci U S A (2015) 0.80
Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep (2015) 0.79
Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma. J Immunol Res (2014) 0.79
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
Essential gene pathways for glioblastoma stem cells: clinical implications for prevention of tumor recurrence. Cancers (Basel) (2011) 0.78
Aggressive invasion is observed in CD133(-)/A2B5(+) glioma-initiating cells. Oncol Lett (2015) 0.78
PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. Oncogene (2015) 0.76
Biological characteristics of a new human glioma cell line transformed into A2B5(+) stem cells. Mol Cancer (2015) 0.76
Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis (2016) 0.76
Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells. Oncotarget (2016) 0.75
Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy. Front Pharmacol (2016) 0.75
Molecular heterogeneity of glioblastomas: does location matter? Oncotarget (2016) 0.75
Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci (2017) 0.75
Targeted Nanotechnology in Glioblastoma Multiforme. Front Pharmacol (2017) 0.75
Adult neurogenesis and glial oncogenesis: when the process fails. Biomed Res Int (2014) 0.75
Isolation and characteristics of CD133‑/A2B5+ and CD133‑/A2B5‑ cells from the SHG139s cell line. Mol Med Rep (2015) 0.75
Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer (2017) 0.75
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
BMP4-BMPR1A signaling in beta cells is required for and augments glucose-stimulated insulin secretion. Cell Metab (2007) 2.39
SRPX2 mutations in disorders of language cortex and cognition. Hum Mol Genet (2006) 2.34
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol (2007) 1.76
Geminivirus VIGS of endogenous genes requires SGS2/SDE1 and SGS3 and defines a new branch in the genetic pathway for silencing in plants. Plant J (2004) 1.71
Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet (2013) 1.70
Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol (2004) 1.65
Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery (2003) 1.58
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer (2004) 1.58
ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int (2010) 1.54
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res (2012) 1.54
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol (2010) 1.48
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab (2010) 1.46
Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets (2010) 1.45
Prognostic significance of tumor-related proteases as a function of the estrogen receptor status. Cancer Biol Ther (2011) 1.42
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol (2007) 1.42
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed (2011) 1.39
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol (2010) 1.36
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev (2006) 1.35
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol (2010) 1.30
Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain (2007) 1.29
Recent trends in epidemiology of brain metastases: an overview. Anticancer Res (2012) 1.26
A semi-automated high-throughput approach to the generation of transposon insertion mutants in the nematode Caenorhabditis elegans. Nucleic Acids Res (2006) 1.25
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol (2010) 1.25
Stereoelectroencephalography in presurgical assessment of MRI-negative epilepsy. Brain (2007) 1.24
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res (2011) 1.24
Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol (2013) 1.22
Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy. Am J Hum Genet (2013) 1.20
French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol (2007) 1.20
Percutaneous kyphoplasty and pedicle screw fixation for the management of thoraco-lumbar burst fractures. Eur Spine J (2010) 1.17
Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies. Brain (2012) 1.17
The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. Genes Dev (2012) 1.16
Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat (2005) 1.15
Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery (2006) 1.15
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (2013) 1.15
Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer (2004) 1.14
Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. Int J Biol Markers (2010) 1.13
Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol (2012) 1.12
Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia. J Neurosurg (2006) 1.12
Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer (2008) 1.12
Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat (2009) 1.11
Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer (2007) 1.09
Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg (2003) 1.09
A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer (2007) 1.08
Alsin/Rac1 signaling controls survival and growth of spinal motoneurons. Ann Neurol (2006) 1.08
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) (2012) 1.08
Striking phenotypic variability in two familial cases of myosin storage myopathy with a MYH7 Leu1793pro mutation. Neuromuscul Disord (2009) 1.07
The usefulness of MR imaging in the diagnosis of dysembryoplastic neuroepithelial tumor in children: a study of 14 cases. AJNR Am J Neuroradiol (2003) 1.07
Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol (2008) 1.07
French research infrastructures to develop and validate glioma biomarkers. Neurosurgery (2014) 1.07
Mutations in CNTNAP1 and ADCY6 are responsible for severe arthrogryposis multiplex congenita with axoglial defects. Hum Mol Genet (2013) 1.06
Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat (2005) 1.06
Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain (2012) 1.06
Local and remote epileptogenicity in focal cortical dysplasias and neurodevelopmental tumours. Brain (2009) 1.06
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res (2011) 1.06
Iodine transfers in the coastal marine environment: the key role of brown algae and of their vanadium-dependent haloperoxidases. Biochimie (2006) 1.05
Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol (2008) 1.05
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol (2013) 1.04
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol (2010) 1.03
Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer (2009) 1.03
Massive inflammatory syndrome and lymphocytic immunodeficiency in KARAP/DAP12-transgenic mice. Eur J Immunol (2002) 1.02
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol (2011) 1.01
Suppression of adult neurogenesis impairs olfactory learning and memory in an adult insect. J Neurosci (2003) 1.01
Electron microscopy in neuromuscular disorders. Ultrastruct Pathol (2005) 1.01
Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol (2010) 1.01
Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery (2007) 1.00
Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab (2007) 1.00
Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg (2003) 0.99
High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol (2009) 0.99
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol (2011) 0.99
Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders. J Neuropathol Exp Neurol (2013) 0.99
French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol (2011) 0.98
Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J (2009) 0.98
A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids with initial normal magnetic resonance imaging. Brain (2011) 0.98
Primary intradural Ewing's sarcoma of the cauda equina presenting with acute bleeding. Acta Neurochir (Wien) (2009) 0.97
Truncation of NHEJ1 in a patient with polymicrogyria. Hum Mutat (2007) 0.97
Assessment of cortical maturation with prenatal MRI. Part I: Normal cortical maturation. Eur Radiol (2005) 0.97
Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies. Arthritis Rheum (2008) 0.96